![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
2024 Pharm Exec Top 50 Companies
Jun 14, 2024 · As we noted in last year’s report, Novo Nordisk and Eli Lilly, competing in the lucrative GLP-1 receptor agonist space that, of late, has captivated the US and beyond in weight loss, are knocking loudly on the top-10 door.Both companies, who own the highest market caps, respectively, in pharma, turned in massive growth in our latest Pharma 50.
Pharmaceutical Executive
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Understanding IDNs and What They Mean to the Pharmaceutical …
Aug 2, 2024 · Integrated Delivery Networks have changed the healthcare landscape over the past decade. Greg Skalicky, president and chief revenue officer at EVERSANA, spoke with Pharmaceutical Executive about the ways that commercialization teams are working with these networks to bring drugs to markets.
Financial Times Global Pharma and Biotech Summit: The Impact of …
Nov 7, 2024 · Donald Trump’s victory in the 2024 US presidential election is sure to have an impact on the pharmaceutical industry. During a panel at the Financial Times’ 2024 Global Pharma and Biotech Summit, the following speakers met to discuss the outcome of the election and the impact it may have on the industry: Lauren Fedor, US political correspondent and Washington deputy bureau chief at The ...
Pharma Marketing Trends to Expect in 2025 - pharmexec.com
Oct 22, 2024 · In a recent video interview with Pharmaceutical Executive, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discussed the importance of patient engagement in pharma marketing. She emphasized the need for personalized marketing strategies that build trust and ensure data privacy. The use of AI and advanced analytics tools was ...
Podcasts - PharmExec
In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the …
Pharma USA 2025 (March 18-19, 2025) - pharmexec.com
Dec 18, 2024 · Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Leading to Commercialization: Q&A with Doug Biehn
Sep 25, 2024 · Octave Bioscience has developed the Multiple Sclerosis Disease Activity Test, a multi-variant blood test that detects for the disease’s activity and, when combined with the company’s AI platform, is able to translate multiple forms of …
Choosing the Right Track: Pharma & Healthcare MBAs - PharmExec
Oct 26, 2018 · A growing range of MBAs with concentrations in pharmaceuticals and healthcare management are on offer. Pharm Exec look at how three of the top programs in the US prepare their students for industry success.
A Formidable First: Winrevair - PharmExec
Aug 16, 2024 · In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.